June 15, 2018 07:26 AM EDTUpdated 11:19 AM

Verrica Pharma bankrolls PhIII with a $75M IPO raise for lead skin drug

Amber Tong

Just in case you’re wondering if the biotech IPO window is still open, dermatology biotech Verrica Pharmaceuticals has bagged $75 million in its Nasdaq …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Verrica Pharma bankrolls PhIII with a $75M IPO raise for lead skin drug

Amber Tong

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Ver­ri­ca Phar­ma bankrolls PhI­II with a $75M IPO raise for lead skin drug

Amber Tong

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Verrica Pharma bankrolls PhIII with a $75M IPO raise for lead skin drug

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?